Hoffmann-la Roche

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Thousands of patients with lung cancer face delays in genomic testing, preventing timely access to targeted treatments that could improve survival rates, according to a report.

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Key innovations from the ASH annual meeting

New research suggested the monoclonal antibody may help ward off progression to myeloma or death.

Lower rates of mortality and cancer recurrence with mastectomy, salpingo-oophorectomy

Benefit seen in all prespecified subgroups, including high-risk patients

But the best strategy for stage I disease is less clear, experts say

But the drug didn't appear to lower the risk of incident nonproliferative diabetic retinopathy

Two-fold increase in PFS with postoperative ivosidenib holds up in placebo-controlled trial

New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease

Plus: oral semaglutide outcomes and incident hypertension in teens on GLP-1 drugs

Treatment with iptacopan reduces proteinuria in interim APPLAUSE-IgAN analysis

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a trials. While other RSV treatments and a vaccine are approved for prevention, EDP-323 could become the first antiviral drug specifically designed to treat RSV infections. The drug has shown a significant reduction in viral load and symptoms in early trials, positioning it as a potential…

A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell lung cancer.

The Forced Swim Test, developed in 1977, models depression using mice or rats to screen for antidepressant medications. It has been known for several decades that this test does not replicate depression, resulting in false negatives and false positives, and is no longer used by most pharmaceutical companies. So why does the National Institutes of Health (NIH) continue to fund studies using it? What's it going to…

Some cases of radiologically isolated syndrome will be considered multiple sclerosis

Poorer survival outcomes plus more toxicity versus rucaparib alone

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care chemotherapy, suggested first phase 3 trial in the field.

Analysis from a phase 2 study showed potential to monitor treatment response in future trials.